-
Information-Publications
-
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibodyDetails -
Impact of Depression on Efficacy of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Multicentre, Prospective Trial (STRESS-LUNG-1)Details -
Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosisDetails -
RNF126-mediated reubiquitination is required for proteasomal degradation of p97-extracted membrane proteinsDetails -
PUPIL enables mapping and stamping of transient electrical connectivity in developing nervous systemsDetails -
A population antibody response against SARS-CoV-2 with differential neutralization activities towards the Delta and Omicron variantsDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands
Back
